VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Merck Files NDA for Keytruda Subcutaneous Formulation Plus Sacituzumab Govitecan in First-Line NSCLC
Merck Files NDA for Keytruda Subcutaneous Formulation Plus Sacituzumab Govitecan in First-Line NSCLC
Jun 05, 2026 10:04 CST Updated 11:07
Share:
Kelun-Biotech
Innovative Drug Developer
